Quantcast
Home / News / Fosamax suit can’t proceed based on ‘sham’ issue

Fosamax suit can’t proceed based on ‘sham’ issue

Irreconcilable contradictions in expert testimony prevented a product liability plaintiff from establishing that Merck failed to provide adequate warnings with the osteoporosis drug Fosamax, the 2nd Circuit has ruled in affirming judgment.


Lawyers USA has ceased publication. If you have purchased a research pass or still have additional time on your current Digital Subscription, you may access locked stories by logging in:







Scroll To Top